Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine

Figures & data

Figure 1. Flow chart of different analysis data sets reflecting the follow-up of the subjects in the trial.

Table 1. Characteristics of study participants at baseline and 5 year.

	At baseline			At 5 year
	Inactivated HA	Attenuated HA	P value	Inactivated HA	Attenuated HA	P value
N	85	97		85	97
Age, month
Mean ± SD	34.7 ± 4.4	35.6 ± 5.4	0.468	96.3 ± 8.5	97.4 ± 8.4	0.392
Height, cm
Mean ± SD	95.4 ± 6.6	96.5 ± 8.6	0.344	130.1 ± 6.7	131.6 ± 8.1	0.189
Weight, kg
Mean ± SD	14.9 ± 2.9	15.6 ± 3.0	0.072	29.1 ± 6.4	31.2 ± 7.8	0.050

Table 2. Five-year antibody persistence of 1 dose inactivated or attenuated hepatitis A vaccine.

Time-point	Parameter	Inactivated HA N = 85	Attenuated HA N = 97	P value
Baseline	GMC, (95% CI)	2.6 (2.5∼2.7)	2.5 (2.5∼2.6)	0.468
1 yr	GMC, (95% CI)	92.1 (74.1∼114.4)	62.7 (52.6∼74.6)	0.007
	Seropositive %, (95% CI)	95.3 (87.7∼99.0)	91.8 (83.9∼96.4)	0.337
2 yr	GMC, (95% CI)	86.0 (68.9∼107.3)	69.1 (58.8∼81.2)	0.115
	Seropositive %, (95% CI)	90.6 (81.8∼95.9)	90.7 (82.7∼95.7)	0.975
5 yr	GMC, (95% CI)	76.3(61.7∼94.4)	66.8 (57.8∼77.3)	0.307
	Seropositive %, (95% CI)	85.9 (76.2∼92.5)	90.7 (82.7∼95.7)	0.308

Figure 2. Five-year change of immune response in inactivated or attenuated hepatitis A vaccine group.